Overview: HHV-8 PCR TestIntroduction: The HHV-8 PCR Test detects HHV-8 DNA to diagnose active infection, linked to Kaposi's sarcoma or lymphoma, helping guide treatment for cancer or infections. Affecting 1 in 10,000 people in endemic areas, HHV-8 poses diagnostic challenges due to latent phases. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses PCR for high sensitivity, supporting virology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in oncology.
Other Names: HHV-8 DNA Test, Active Infection Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: HHV-8 DNA detection began in the 1990s with research by Moore, who developed PCR methods. PCR advancements in the 2000s by Roche improved detection, surpassing earlier serology methods.
Purpose: Detects HHV-8 DNA to diagnose active infection, guides antiviral or cancer therapy, and evaluates patients with skin lesions, aiming to manage disease.
Test Parameters: HHV-8 DNA presence
Pretest Condition: No special preparation required. Collect whole blood or tissue. Report history of cancer or lesions.
Specimen: Whole Blood (EDTA, 3-5 mL), Tissue (FFPE, 0.5-2 cma³); 4 mL whole blood in EDTA tube or swab in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document skin lesions or cancer history. Include current medications or immune status.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., lymphoma), and sample collection risks.
Procedural Considerations: Uses PCR to detect DNA, requiring labs with thermal cyclers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive DNA confirms active infection, guiding therapy. Early treatment might prevent progression, while untreated cases lead to cancer. Negative results may require serology.
Specialist Consultation: Consult an oncologist or infectious disease specialist for interpretation.
Additional Supporting Tests: HHV-8 IgG/IgM, biopsy, or imaging to confirm diagnosis.
Test Limitations: Specific to active infection; correlation with symptoms needed. False negatives possible with low viral load.
References: CDC Guidelines, 2023; Journal of Virology, Moore PS, 2022.
